Story
C4 Therapeutics Stock Gains on Q2 Earnings Beat Despite Revenue Miss

C4 Therapeutics (ticker: CCCC) shares rose in morning trading after the clinical-stage biopharmaceutical company reported second-quarter financial results that featured a narrower-than-expected loss, even as revenue fell short of analyst forecasts. Management's reaffirmation of its clinical trial timeline provided an additional tailwind for the stock.
Mixed Quarterly Results
The company posted a net loss of $0.18 per share for the second quarter of 2026, outperforming the consensus analyst estimate of a $0.21 loss per share, according to its earnings release. This positive earnings surprise was the primary driver for the stock's move higher.
However, total revenue for the period was $6.64 million, missing the consensus forecast of $8.2 million. C4 Therapeutics noted that revenue was partially affected by the winding down of certain research activities under its collaborations with Merck and Merck KGaA. In response to the report, the stock gained 3.8% in morning trading, reaching a session high of $3.90.
Pipeline Outlook Provides Support
Investors also focused on the company's clinical development pipeline. CEO Andrew Hirsch confirmed that key trials for its lead candidate, cemsidomide, remain on schedule.
AdKey upcoming milestones include:
- The ongoing Phase 2 MOMENTUM trial.
- A Phase 1b combination study with elranatamab.
Both studies are on track to deliver clinical data readouts in 2027, providing investors with clear forward-looking catalysts to monitor.
Market Context
The advance in C4 Therapeutics shares was a company-specific reaction, standing out in a largely flat market. The S&P 500 was little changed and the NASDAQ traded slightly lower, indicating no broad market or sector-wide momentum was lifting the stock. The source material also noted no major news from peer companies in the targeted protein degradation space that would have influenced C4's performance.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.